SCHEMBL4802629

SCHEMBL4802629

CNC(=O)C(Br)CC(C)C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 11/20 0.40
MMP9 P14780 11/20 0.40
MMP2 P08253 9/20 0.40
MMP8 P22894 6/20 0.40
KISS1R Q969F8 3/20 0.38
MMP3 P08254 10/20 0.38
MMP13 P45452 3/20 0.38
ADAM17 P78536 3/20 0.37
MMP7 P09237 2/20 0.37
MMP14 P50281 2/20 0.37
TNF P01375 2/20 0.37
MMP20 O60882 1/20 0.37
ADAMTS4 O75173 1/20 0.37
MMP10 P09238 1/20 0.37
MMP12 P39900 1/20 0.37
MMP15 P51511 1/20 0.37
MMP16 P51512 1/20 0.37
MMP25 Q9NPA2 1/20 0.37
MMP26 Q9NRE1 1/20 0.37
ADAMTS5 Q9UNA0 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14365163 1.00 MMP1 (0.40) MMP1MMP9MMP2MMP8KISS1R
SCHEMBL14365019 0.75 MMP9 (0.42) MMP1MMP9MMP2MMP8KISS1R
SCHEMBL1770755 0.75
SCHEMBL4660964 0.75 MMP9 (0.42) MMP1MMP9MMP2MMP8KISS1R
SCHEMBL16300127 0.75 MMP9 (0.42) MMP1MMP9MMP2MMP8KISS1R
SCHEMBL26004765 0.73 MMP9 (0.44) MMP1MMP9MMP2MMP8KISS1R
SCHEMBL26004787 0.73 MMP9 (0.44) MMP1MMP9MMP2MMP8KISS1R
SCHEMBL18391421 0.73 MMP9 (0.44) MMP1MMP9MMP2MMP8KISS1R
SCHEMBL25327561 0.72
SCHEMBL2637647 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7378418-B2 Azabicyclic heterocycles as cannabinoid receptor modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2008-05-27 US disclosed
US-7378418-B2 Azabicyclic heterocycles as cannabinoid receptor modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2008-05-27 US disclosed
US-7378418-B2 Azabicyclic heterocycles as cannabinoid receptor modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2008-05-27 US disclosed
EP-1697370-B1 AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS BRISTOL MYERS SQUIBB CO (US) 2007-04-25 EP disclosed
EP-1697370-B1 AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS BRISTOL MYERS SQUIBB CO (US) 2007-04-25 EP disclosed
EP-1697370-A1 AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS Bristol-Myers Squibb Company (US) 2006-09-06 EP disclosed
WO-2005063761-A1 AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2005-07-14 WO disclosed
US-20050143381-A1 Azabicyclic heterocycles as cannabinoid receptor modulators BROSTOL-MYERS SQUIBB COMPANY 2005-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143381-A1 Azabicyclic heterocycles as cannabinoid receptor modulators CNR1, CNR2, CCKBR MMP1 4818/4885MMP9 4427/4885MMP2 4649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.